Distinct properties of pure- and mixed-type high-grade fetal lung adenocarcinomas by genetic profiling and transcription factor expression

被引:5
作者
Kishikawa, Satsuki [1 ]
Hayashi, Takuo [1 ]
Saito, Tsuyoshi [1 ]
Takamochi, Kazuya [2 ]
Sasa, Keita [1 ,3 ]
Suehara, Yoshiyuki [3 ]
Takahashi, Fumiyuki [4 ]
Sasahara, Noriko [1 ]
Kohsaka, Shinji [5 ]
Suzuki, Kenji [2 ]
Yao, Takashi [1 ]
机构
[1] Juntendo Univ, Dept Human Pathol, Grad Sch Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan
[2] Juntendo Univ, Dept Gen Thorac Surg, Grad Sch Med, Bunkyo Ku, Tokyo 1138421, Japan
[3] Juntendo Univ, Dept Med Orthopaed & Motor Organ, Grad Sch Med, Bunkyo Ku, Tokyo 1138421, Japan
[4] Juntendo Univ, Dept Resp Med, Grad Sch Med, Bunkyo Ku, Tokyo 1138421, Japan
[5] Natl Canc Ctr, Div Cellular Signaling, Res Inst, Chuo Ku, Tokyo 1040045, Japan
基金
日本学术振兴会;
关键词
Fetal lung adenocarcinoma; High-grade fetal lung adenocarcinoma; CDX2; TTF-1; BETA-CATENIN; PHENOTYPE; CARCINOMA; MUTATION;
D O I
10.1007/s00428-021-03247-7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The clinicopathological differences among high-grade fetal lung adenocarcinomas completely comprising tumor cells that resemble fetal lung epithelium (pure type) and those with fetal lung-like components admixed with conventional adenocarcinoma cells (mixed type) remain undetermined. Here, we examined the clinicopathological, immunohistochemical, and molecular features of 11 lung adenocarcinomas with fetal lung-like morphology among 3895 consecutive cases of primary lung cancer based on the expression pattern of transcription factors. According to the current WHO classification, two cases (0.05%) were categorized as low-grade fetal adenocarcinoma, two cases (0.05%) were pure-type high-grade fetal adenocarcinoma, five cases (0.1%) were mixed-type high-grade fetal adenocarcinoma, and the remaining two cases (0.05%) were lung adenocarcinoma with high-grade fetal features (fetal lung-like morphology occupied less than 50%). CTNNB1 mutations were exclusively identified in low-grade fetal adenocarcinomas. In contrast, mixed-type high-grade fetal adenocarcinoma or lung adenocarcinoma with high-grade fetal features frequently harbored mitogenic drivers including EGFR mutations. Furthermore, almost all tumor cells expressed CDX2 and HNF4 alpha in both cases of pure-type high-grade fetal lung adenocarcinoma, but lacked TTF-1 positivity. In contrast, TTF-1 was frequently expressed in mixed-type high-grade fetal lung adenocarcinoma and in lung adenocarcinoma with high-grade fetal features. Our data suggest similar prevalence of low-grade fetal lung adenocarcinoma and pure-type high-grade fetal lung adenocarcinoma, and indicate that pure- and mixed-type high-grade fetal lung adenocarcinomas are distinct, with the former akin to low-grade fetal adenocarcinoma with respect to purely embryonic morphology and absence of common lung adenocarcinoma mitogenic drivers, and the latter being genetically and transcriptionally related to conventional lung adenocarcinoma.
引用
收藏
页码:609 / 619
页数:11
相关论文
共 32 条
[1]   SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization [J].
Baine, Marina K. ;
Hsieh, Min-Shu ;
Lai, W. Victoria ;
Egger, Jacklynn V. ;
Jungbluth, Achim A. ;
Daneshbod, Yahya ;
Beras, Amanda ;
Spencer, Rowanne ;
Lopardo, Jessica ;
Bodd, Francis ;
Montecalvo, Joseph ;
Sauter, Jennifer L. ;
Chang, Jason C. ;
Buonocore, Darren J. ;
Travis, William D. ;
Sen, Triparna ;
Poirier, John T. ;
Rudin, Charles M. ;
Rekhtman, Natasha .
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (12) :1823-1835
[2]  
Boland CR, 1998, CANCER RES, V58, P5248
[3]   Core transcriptional regulatory circuitries in cancer [J].
Chen, Ye ;
Xu, Liang ;
Lin, Ruby Yu-Tong ;
Muschen, Markus ;
Koeffler, H. Phillip .
ONCOGENE, 2020, 39 (43) :6633-6646
[4]   Establishment of Intestinal Identity and Epithelial-Mesenchymal Signaling by Cdx2 [J].
Gao, Nan ;
White, Peter ;
Kaestner, Klaus H. .
DEVELOPMENTAL CELL, 2009, 16 (04) :588-599
[5]   Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities [J].
Gay, Carl M. ;
Stewart, C. Allison ;
Park, Elizabeth M. ;
Diao, Lixia ;
Groves, Sarah M. ;
Heeke, Simon ;
Nabet, Barzin Y. ;
Fujimoto, Junya ;
Solis, Luisa M. ;
Lu, Wei ;
Xi, Yuanxin ;
Cardnell, Robert J. ;
Wang, Qi ;
Fabbri, Giulia ;
Cargill, Kasey R. ;
Vokes, Natalie, I ;
Ramkumar, Kavya ;
Zhang, Bingnan ;
Della Corte, Carminia M. ;
Robson, Paul ;
Swisher, Stephen G. ;
Roth, Jack A. ;
Glisson, Bonnie S. ;
Shames, David S. ;
Wistuba, Ignacio I. ;
Wang, Jing ;
Quaranta, Vito ;
Minna, John ;
Heymach, John, V ;
Byers, Lauren Averett .
CANCER CELL, 2021, 39 (03) :346-+
[6]   Inverse correlation between galectin-4 and TTF-1 in lung adenocarcinoma [J].
Hara, Kieko ;
Saito, Tsuyoshi ;
Hayashi, Takuo ;
Mitani, Keiko ;
Takamochi, Kazuya ;
Oh, Shiaki ;
Suzuki, Kenji ;
Yao, Takashi .
VIRCHOWS ARCHIV, 2017, 471 (03) :375-382
[7]   A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix [J].
Hara, Kieko ;
Saito, Tsuyoshi ;
Hayashi, Takuo ;
Yimit, Alkam ;
Takahashi, Michiko ;
Mitani, Keiko ;
Takahashi, Makoto ;
Yao, Takashi .
PATHOLOGY RESEARCH AND PRACTICE, 2015, 211 (09) :657-664
[8]   Non-small cell lung carcinoma with diffuse coexpression of thyroid transcription factor-1 and ΔNp63/p40 [J].
Hayashi, Takuo ;
Takamochi, Kazuya ;
Yanai, Yuka ;
Mitani, Keiko ;
Tomita, Hisashi ;
Mogushi, Kaoru ;
Suehara, Yoshiyuki ;
Takahashi, Fumiyuki ;
Suzuki, Kenji ;
Saito, Tsuyoshi ;
Yao, Takashi .
HUMAN PATHOLOGY, 2018, 78 :177-181
[9]   E-cadherin can limit the transforming properties of activating β-catenin mutations [J].
Huels, David J. ;
Ridgway, Rachel A. ;
Radulescu, Sorina ;
Leushacke, Marc ;
Campbell, Andrew D. ;
Biswas, Sujata ;
Leedham, Simon ;
Serra, Stefano ;
Chetty, Runjan ;
Moreaux, Guenievre ;
Parry, Lee ;
Matthews, James ;
Song, Fei ;
Hedley, Ann ;
Kalna, Gabriela ;
Ceteci, Fatih ;
Reed, Karen R. ;
Meniel, Valerie S. ;
Maguire, Aoife ;
Doyle, Brendan ;
Soderberg, Ola ;
Barker, Nick ;
Watson, Alastair ;
Larue, Lionel ;
Clarke, Alan R. ;
Sansom, Owen J. .
EMBO JOURNAL, 2015, 34 (18) :2321-2333
[10]   Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies [J].
Jordan, Emmet J. ;
Kim, Hyunjae R. ;
Arcila, Maria E. ;
Barron, David ;
Chakravarty, Debyani ;
Gao, JianJiong ;
Chang, Matthew T. ;
Ni, Andy ;
Kundra, Ritika ;
Jonsson, Philip ;
Jayakumaran, Gowtham ;
Gao, Sizhi Paul ;
Johnsen, Hannah C. ;
Hanrahan, Aphrothiti J. ;
Zehir, Ahmet ;
Rekhtman, Natasha ;
Ginsberg, Michelle S. ;
Li, Bob T. ;
Yu, Helena A. ;
Paik, Paul K. ;
Drilon, Alexander ;
Hellmann, Matthew D. ;
Reales, Dalicia N. ;
Benayed, Ryma ;
Rusch, Valerie W. ;
Kris, Mark G. ;
Chaft, Jamie E. ;
Baselga, Jose ;
Taylor, Barry S. ;
Schultz, Nikolaus ;
Rudin, Charles M. ;
Hyman, David M. ;
Berger, Michael F. ;
Solit, David B. ;
Ladanyi, Marc ;
Riely, Gregory J. .
CANCER DISCOVERY, 2017, 7 (06) :596-609